Investigational and unapproved. Findings below describe what trials and reports have observed. Nothing here is an endorsement, a claim of safety or effectiveness, or a clinical recommendation.
Pemvidutide
INVESTIGATIONAL
GLP-1/glucagon dual agonist
11
graded findings
7
effect domains
Evidence spread
High evidence 0Moderate evidence 2Low evidence 3Very low evidence 6
Pemvidutide is shown as an investigational or pipeline evidence record. Findings describe what studies and reports observed; they do not endorse use or establish personal suitability.
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
PemvidutideINVESTIGATIONAL
Lipids and lipoproteinsDecrease
Low evidence
Pemvidutide produced large TG and LDL/total-cholesterol reductions in phase 2 MOMENTUM obesity (glucagon-driven lipid effect).
Fundingindustry - Altimmune (trial sponsor; inferred from registration trial)
Scope limitsconference/abstract-level; identifier not fully verified; no outcome data yet (ongoing); small sample (N~50)
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
PemvidutideINVESTIGATIONAL
Body compositionDecrease
Very low evidence
MOMENTUM phase 2 MRI-based body-composition substudy: pemvidutide reported ~78.1% of weight lost as fat and ~21.9% as lean mass, framed by the sponsor as...
Full findingMOMENTUM phase 2 MRI-based body-composition substudy: pemvidutide reported ~78.1% of weight lost as fat and ~21.9% as lean mass, framed by the sponsor as 'class-leading' lean-mass preservation.
Fundingindustry - Altimmune (trial sponsor; inferred from registration trial)
Scope limitsconference/abstract-level; identifier not fully verified; no outcome data yet (ongoing); small sample (N~50)
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
PemvidutideINVESTIGATIONAL
Weight changeDecrease
Moderate evidence
In a 24-week MASLD trial, pemvidutide produced ~6% weight loss as a secondary outcome.
SourcePemvidutide in MASLD, 24-week, J Hepatol Rep 2025Source
PopulationPeer-reviewed RCT / meta-analysis
FundingAltimmune
Scope limitsMASLD-context weight secondary, not an obesity-primary result. The pemvidutide obesity-primary (MOMENTUM) remains conference/press-only and non-graduating.
PemvidutideINVESTIGATIONAL
Weight changeDecrease
Very low evidence
Dose-dependent weight loss over 48 wk in obesity/overweight without diabetes (MOMENTUM)
Fundingindustry - Altimmune (trial sponsor; inferred from registration trial)
Scope limitsconference/abstract-level; identifier not fully verified; no outcome data yet (ongoing); small sample (N~50)
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
PemvidutideINVESTIGATIONAL
hepatic-mashMixed
Moderate evidence
In IMPACT (phase 2b, F2-F3), the GLP-1/glucagon dual pemvidutide MET one dual-primary (MASH resolution) but DID NOT MEET the other (fibrosis improvement) at 24 weeks;...
SourceNoureddin M, Harrison SA, Loomba R et al. Pemvidutide vs placebo for MASH (IMPACT): 24-we...Source
Full findingIn IMPACT (phase 2b, F2-F3), the GLP-1/glucagon dual pemvidutide MET one dual-primary (MASH resolution) but DID NOT MEET the other (fibrosis improvement) at 24 weeks; the fibrosis differences vs placebo were small and non-significant (p=0.59 and p=0.27). Reported honestly: fibrosis was a MISS at 24 weeks.
The Echo Compendium